ASCENDIS PHARMA A/S (ASND:NASDAQ)
$235.26 -4.39 (-1.8318%)
Analysed ASCENDIS PHARMA A/S (ASND:NASDAQ) News Sources
European Equities Traded in the US as American Depositary Receipts Heading Lower in Thursday Trading
07-05-2026
yahoo.com
Ascendis (ASND) Q1 2026 Earnings Call Transcript
08-05-2026
fool.com
Energy Fund Yielding 7% and Up 14% in a Year Still Wasn’t Enough to Stop This $3 Million Exit
09-05-2026
fool.com
European Equities Traded in the US as American Depositary Receipts Flat in Wednesday Trading
13-05-2026
yahoo.com
What to Know About This Fund’s $50 Million Exit From Ascendis Pharma
14-05-2026
fool.com
Ascendis Pharma (NASDAQ:ASND) Is Posting Healthy Earnings, But It Is Not All Good News
15-05-2026
yahoo.com
European Equities Traded in the US as American Depositary Receipts Open Week Tracking Higher in Monday Trading
18-05-2026
yahoo.com
StubHub, Jazz Pharmaceuticals upgraded: Wall Street's top analyst calls
19-05-2026
yahoo.com
Spyglass Capital Dumps $26 Million of Global-e Online Amid Stock's 24% Decline
20-05-2026
fool.com
European Equities Traded in the US as American Depositary Receipts Track Higher in Tuesday Trading
26-05-2026
yahoo.com
What is the current price of ASCENDIS PHARMA A/S (ASND:NASDAQ)?
The current price of ASCENDIS PHARMA A/S (ASND:NASDAQ) is $235.26.
ASCENDIS PHARMA A/S (ASND:NASDAQ) absolute price change since previous trading day?
The absolute price change of ASCENDIS PHARMA A/S (ASND:NASDAQ) since the previous trading day is $-4.39.
ASCENDIS PHARMA A/S (ASND:NASDAQ) percentage price change since previous trading day?
The percentage price change of ASCENDIS PHARMA A/S (ASND:NASDAQ) since the previous trading day is -1.8318%.
What is the most recent average sentiment score for ASCENDIS PHARMA A/S (ASND:NASDAQ)?
The most recent average sentiment score for ASCENDIS PHARMA A/S (ASND:NASDAQ) is 33 out of 100.
What is the most recent average sentiment for ASCENDIS PHARMA A/S (ASND:NASDAQ)?
The most recent sentiment for ASCENDIS PHARMA A/S (ASND:NASDAQ) is .
SEC-8K** Filing Available For ASCENDIS PHARMA A/S (ASND:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.